Cargando…

Management of Acute Pancreatitis Associated With Checkpoint Inhibitors

Pancreatitis is a rare immune-related adverse event (irAE) associated with the use of immune checkpoint inhibitors (ICIs). It is more often associated with combined immunotherapy than by any single agent. Early signs of pancreatitis may only include elevation of lipase and amylase. Additional sympto...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Barbara Barnes, Cuddahy, Terri, Zawislak, Carolyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517772/
https://www.ncbi.nlm.nih.gov/pubmed/33542849
http://dx.doi.org/10.6004/jadpro.2020.11.1.3
_version_ 1783587291237711872
author Rogers, Barbara Barnes
Cuddahy, Terri
Zawislak, Carolyn
author_facet Rogers, Barbara Barnes
Cuddahy, Terri
Zawislak, Carolyn
author_sort Rogers, Barbara Barnes
collection PubMed
description Pancreatitis is a rare immune-related adverse event (irAE) associated with the use of immune checkpoint inhibitors (ICIs). It is more often associated with combined immunotherapy than by any single agent. Early signs of pancreatitis may only include elevation of lipase and amylase. Additional symptoms associated with pancreatitis include symptoms such as severe epigastric abdominal pain (that may radiate to the back, chest, or flank), nausea and/or vomiting, or dyspnea, and may indicate more advanced disease. Some researchers note that the presence of symptoms is not an indicator of more severe pancreatitis or long-term adverse outcomes. Radiologic changes can be useful in the diagnostic workup of ICI-associated pancreatitis, but radiologic tests may not show any changes in some patients with active pancreatitis. The management of ICI-associated pancreatitis can include those interventions used to manage acute pancreatitis (e.g., IV fluids, holding the agent, antibiotics, and steroids). The National Comprehensive Cancer Network Guidelines only recommend intervention for moderate to severe pancreatitis. Holding the associated ICI(s) is the most commonly used intervention when patients experience pancreatitis that is thought to be related to ICIs. Steroids are usually used in the management of irAEs associated with checkpoint inhibitors; however, there are no studies available at this time to indicate that this is the best method to treat pancreatitis associated with ICIs. Additional studies are needed to determine if steroids are the best method to manage irAE-associated pancreatitis or if additional management strategies are important in the management of pancreatitis in patients receiving checkpoint inhibitors.
format Online
Article
Text
id pubmed-7517772
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-75177722021-02-03 Management of Acute Pancreatitis Associated With Checkpoint Inhibitors Rogers, Barbara Barnes Cuddahy, Terri Zawislak, Carolyn J Adv Pract Oncol Grand Rounds Pancreatitis is a rare immune-related adverse event (irAE) associated with the use of immune checkpoint inhibitors (ICIs). It is more often associated with combined immunotherapy than by any single agent. Early signs of pancreatitis may only include elevation of lipase and amylase. Additional symptoms associated with pancreatitis include symptoms such as severe epigastric abdominal pain (that may radiate to the back, chest, or flank), nausea and/or vomiting, or dyspnea, and may indicate more advanced disease. Some researchers note that the presence of symptoms is not an indicator of more severe pancreatitis or long-term adverse outcomes. Radiologic changes can be useful in the diagnostic workup of ICI-associated pancreatitis, but radiologic tests may not show any changes in some patients with active pancreatitis. The management of ICI-associated pancreatitis can include those interventions used to manage acute pancreatitis (e.g., IV fluids, holding the agent, antibiotics, and steroids). The National Comprehensive Cancer Network Guidelines only recommend intervention for moderate to severe pancreatitis. Holding the associated ICI(s) is the most commonly used intervention when patients experience pancreatitis that is thought to be related to ICIs. Steroids are usually used in the management of irAEs associated with checkpoint inhibitors; however, there are no studies available at this time to indicate that this is the best method to treat pancreatitis associated with ICIs. Additional studies are needed to determine if steroids are the best method to manage irAE-associated pancreatitis or if additional management strategies are important in the management of pancreatitis in patients receiving checkpoint inhibitors. Harborside Press LLC 2020 2020-01-01 /pmc/articles/PMC7517772/ /pubmed/33542849 http://dx.doi.org/10.6004/jadpro.2020.11.1.3 Text en © 2020 Harborside™ http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Grand Rounds
Rogers, Barbara Barnes
Cuddahy, Terri
Zawislak, Carolyn
Management of Acute Pancreatitis Associated With Checkpoint Inhibitors
title Management of Acute Pancreatitis Associated With Checkpoint Inhibitors
title_full Management of Acute Pancreatitis Associated With Checkpoint Inhibitors
title_fullStr Management of Acute Pancreatitis Associated With Checkpoint Inhibitors
title_full_unstemmed Management of Acute Pancreatitis Associated With Checkpoint Inhibitors
title_short Management of Acute Pancreatitis Associated With Checkpoint Inhibitors
title_sort management of acute pancreatitis associated with checkpoint inhibitors
topic Grand Rounds
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517772/
https://www.ncbi.nlm.nih.gov/pubmed/33542849
http://dx.doi.org/10.6004/jadpro.2020.11.1.3
work_keys_str_mv AT rogersbarbarabarnes managementofacutepancreatitisassociatedwithcheckpointinhibitors
AT cuddahyterri managementofacutepancreatitisassociatedwithcheckpointinhibitors
AT zawislakcarolyn managementofacutepancreatitisassociatedwithcheckpointinhibitors